1. Home
  2. SNY vs MRNA Comparison

SNY vs MRNA Comparison

Compare SNY & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sanofi ADS

SNY

Sanofi ADS

N/A

Current Price

$46.64

Market Cap

95.7B

Sector

Health Care

ML Signal

N/A

Logo Moderna Inc.

MRNA

Moderna Inc.

N/A

Current Price

$196.25

Market Cap

91.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SNY
MRNA
Founded
1994
2010
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.7B
91.2B
IPO Year
2001
2018

Fundamental Metrics

Financial Performance
Metric
SNY
MRNA
Price
$46.64
$196.25
Analyst Decision
Buy
Hold
Analyst Count
11
23
Target Price
$54.92
★ $164.53
AVG Volume (30 Days)
4.2M
★ 11.3M
Earning Date
10-30-2026
11-06-2026
Dividend Yield
★ 5.25%
N/A
EPS Growth
N/A
★ 21.77
EPS
★ N/A
N/A
Revenue
N/A
★ $19,263,000,000.00
Revenue This Year
$3.97
$24.09
Revenue Next Year
$6.77
$11.33
P/E Ratio
$6.14
★ N/A
Revenue Growth
N/A
★ 4.29
52 Week Low
$39.07
$23.55
52 Week High
$50.61
$280.80

Technical Indicators

Market Signals
Indicator
SNY
MRNA
Relative Strength Index (RSI) 57.70 41.43
Support Level $45.95 $181.02
Resistance Level $48.57 $254.48
Average True Range (ATR) 0.86 18.33
MACD -0.20 -7.45
Stochastic Oscillator 40.49 5.92

Price Performance

Historical Comparison
SNY
MRNA

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

About MRNA Moderna Inc.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Share on Social Networks: